In addition, galectin-7 proved to accelerate tumor progression in one of the most aggressive forms of breast cancer (HER-2 positive) as was published in a subsequent study, using genetically engineered galectin-7–deficient mice [61]. This evidence concerns the gene ERBB2 and breast carcinoma.